$XLRN ACCELERON PHARMA INC Insider Trading Week 37/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC in week 37/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 39.96 | 100 | 3,996 | 26,967 | 27.1 K to 27 K (-0.37 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 39.30 | 1,165 | 45,785 | 27,067 | 28.2 K to 27.1 K (-4.13 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Rovaldi Christopher | SVP, Program Mgmt a ... | Sell | S | 38.32 | 12,735 | 488,005 | 28,232 | 41 K to 28.2 K (-31.09 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.12 | 8 | 305 | 90,214 | 90.2 K to 90.2 K (-0.01 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 39.39 | 500 | 19,695 | 90,222 | 90.7 K to 90.2 K (-0.55 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.31 | 4,605 | 176,418 | 90,722 | 95.3 K to 90.7 K (-4.83 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.03 | 8 | 304 | 57,310 | 57.3 K to 57.3 K (-0.01 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 39.37 | 600 | 23,622 | 57,318 | 57.9 K to 57.3 K (-1.04 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.29 | 4,505 | 172,496 | 57,918 | 62.4 K to 57.9 K (-7.22 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 39.91 | 150 | 5,987 | 78,000 | 78.2 K to 78 K (-0.19 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 39.24 | 1,600 | 62,784 | 78,150 | 79.8 K to 78.2 K (-2.01 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 38.32 | 16,650 | 638,028 | 79,750 | 96.4 K to 79.8 K (-17.27 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.85 | 210 | 8,369 | 49,300 | 49.5 K to 49.3 K (-0.42 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.17 | 1,300 | 50,921 | 49,510 | 50.8 K to 49.5 K (-2.56 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 38.32 | 14,490 | 555,257 | 50,810 | 65.3 K to 50.8 K (-22.19 %) |